저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

Size: px
Start display at page:

Download "저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할"

Transcription

1 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우, 이저작물에적용된이용허락조건을명확하게나타내어야합니다. 저작권자로부터별도의허가를받으면이러한조건들은적용되지않습니다. 저작권법에따른이용자의권리는위의내용에의하여영향을받지않습니다. 이것은이용허락규약 (Legal Code) 을이해하기쉽게요약한것입니다. Disclaimer

2 Study on the mechanism of cancer cell death induced by TGFβ1, TGFβ2 downregulation Zhezhu Han Department of Medical Science The Graduate School, Yonsei University

3 Study on the mechanism of cancer cell death induced by TGFβ1, TGFβ2 downregulation Directed by Professor Jae Jin Song The Doctoral Dissertation submitted to the Department of Medical Science, the Graduate School of Yonsei University in partial fulfillment of the requirements for the degree of Doctor of Philosophy Zhezhu Han June 2017

4 This certifies that the Doctoral Dissertation of Zhezhu Han is approved Thesis Supervisor : Jae Jin Song Thesis Committee Member#1 : Ho Guen Kim Thesis Committee Member#2 : Ki Taek Nam Thesis Committee Member#3 : Hye Jin Choi Thesis Committee Member#4 : Hyun Seok Kim The Graduate School Yonsei University June 2017

5 ACKNOWLEDGEMENTS 설렘을안고시작했던학위과정, 이제비로소모든과정을마치며지난시간을되돌아봅니다. 처음한국에왔을때부터오늘까지약 3년반이란시간은저에게는학문의길뿐만아니라생장의시간이었고감사한삶이었습니다. 그시간동안옆에서도와주신많은분들이아니었다면지금순간이있을수없다고생각합니다. 미흡하지만학위논문을마치면서그분들께감사의말씀을전합니다. 누구보다도많은도움을주시고, 부족한점을언제나세심하고꼼꼼한손길로지적해주시고항상저의연구방향과내용에대하여조언을해주시고진행과정에많은도움을주시고생활방면에서도관심을주신저의지도교수님송재진교수님께감사드립니다. 그리고바쁘신와중에도따뜻한격려와조언을해주신김주항교수님께도감사드립니다. 또한저의연구내용에대하여조언을해주시고여러모로많은도움을주신최혜진교수님께감사드립니다. 그리고제논문을심사하시면서저의연구내용에대한조언과격려를아끼지않으셨던김호근교수님, 남기택교수님과김현석교수님께진심으로감사를드립니다. 유학생활을시작하기전에많은걱정을했었는데좋은실험실선후배를만나 3년반이라는시간이짧게느껴질정도로즐겁게할수있었습니다. 실험에대한조언과도움을많이준소영씨, 같은고향에서와서힘이되고많은실험기법과지식을가르쳐준동욱형, 지금은이미졸업한예의바르고열심히실험실생활을하였던수진씨, 은경씨, 승하씨, 수연씨, 그리고부족한선배를이해해주고잘따라준연수, 지현, 항상열심히하는수완이, 좀더

6 노력해야하는근혁이, 이제막새롭게실험실에서연구를시작하려는수진씨, 모두에게진심으로감사의마음을전합니다. 언제나챙겨주시던장인, 장모님, 항상응원해주시고도움을주신광수형, 미화형수, 룡남형, 련희형수한테감사의말을전합니다. 항상저를믿어주시고묵묵히응원해주시는사랑하는부모님께감사드립니다. 제멋대로인아들인데항상이해해주시고믿어주셔서제가여기까지할수있었고, 한발짝더나아가겠다는결심도할수있었습니다. 열심히, 그리고잘하여서부모님께서해주신은혜에보답할수있는자랑스러운아들이되도록하겠습니다. 제소중한인연, 와이프장설매한테도감사를드립니다. 항상변함없는마음으로같은자리를지켜주셔서제가마음편히연구할수있었습니다. 그리고제가한국에서박사공부를할수있게길을마련해주신심웅호과장님께도감사드립니다. 이외에도여기에미처적지못한많은분들께감사드립니다. 여러분이있어제가있었고, 저도여러분께힘이될수있는존재가될수있도록하겠습니다. 감사하고사랑합니다.

7 TABLE OF CONTENTS ABSTRACT i I. INTRODUCTION 1 II. MATERIALS AND METHODS 8 1. Cell culture 8 2. Plasmids and recombinant proteins 8 3. Construction of adenoviral vectors 8 4. Name of recombinant adenovirus 9 5. MTS viability assay 9 6. Western blot analysis Real-time polymerase chain reaction(rt-pcr) Clonogenic assay Measurement of intracellular level of ROS Enzyme-linked immunosorbent assay (ELISA) Immunopricipitation (IP) Chromatin immunoprecipitation(chip) assay Animal study Immunohistochemistry (IHC) Statistical analysis 16 III. RESULTS 17

8 1. TGF-β1 or 2 expression in cells after infection with an adenovirus expressing shtgf-β1 or Adenovirus expressing shrna of TGF-β1 or 2 can induce several signaling pathways change in melanoma and pancreatic cancer cell lines No off-targeting effect of adenovirus-expressing shtgf-β1 or 2 in melanoma cancer cell lines Increased ROS generation was induced by adenovirus expressing shrna of TGF-β1 or Effects of NAC on cell growth and apoptosis in Adenovirus expressing shrna of TGF-β1 or 2 treated melanoma and pancreatic cancer cells Dissociation of Trx from ASK1 Trx complexes induced by Adenovirus expressing shrna of TGF-β1 or 2 infection Regulation of Trx, GSTM1 promoter activity, Ap1, Sp1 and Smad molecule expression by TGFβ No effect of expressing shrna of TGF-β1 or 2 adenovirus treatment induced ROS on Trx, GSTM1 expression ASK1 mediates TGFβ induced cell death via p38 MAPK/JNK activation 36

9 10. Enhanced anti-tumor effect induced by adenovirus expressing shtgf-β1 or 2 42 IV. DISCUSSION 46 V. CONCLUSION 50 REFERENCES 51 ABSTRACT (IN KOREAN) 60 PUBLICATION LIST 62

10 LIST OF FIGURES Figure 1. Downregulation of human transforming growth facto r (htgf)-β1 or 2 short hairpin RNA(shRNA) 18 Figure 2. Effect of adenovirus-expressing shtgf-β1 or 2 in me lanoma and pancreatic cancer cell lines 21 Figure 3. No off-targeting effect of adenovirus-expressing sht GF-β1 or 2 in melanoma cancer cell lines 24 Figure 4. ROS generation was induced by shtgf-β1 and sht GF-β2 expressing adenoviruses 26 Figure 5. Effects of NAC treatment with Adenovirus expressing shrna of TGF-β1 or 2 in melanoma and panc reatic cancer cells 27 Figure 6. Effect of Adenovirus expressed shrna of TGF-β1 or 2 treatment induced association of ASK1 with Trx and GSTM1 30 Figure 7. Regulation of Trx, GSTM1 promoter activity by TGF β 33 Figure 8. Effects of NAC on Trx, GSTM1 expression with ex pressing shhtgf-β1 or 2 adenovirus infection in melanoma and pancreatic cancer cells 35 Figure 9. ASK1 mediates TGFβ induced cell death via p38 MA PK/JNK activation 41 Figure 10. Anti-tumor effect of adenovirus expressing shtgfβ1 or 2 in Xenograft animal models 44

11 Figure 11. Schematic diagram of determination of cancer cell death by TGF-β downregulation 49

12 ABSTRACT Study on the mechanism of cancer cell death induced by TGFβ1, TGFβ2 downregulation Zhezhu Han Department of Medical Science The Graduate School, Yonsei University (Directed by Professor Jae Jin Song) TGF-β signaling has been increasingly recognized as a key driver in cancer. Unlike its tumor suppressor function in normal tissue, TGF-β activation incites tumor progression in cancer tissue and an increase in TGF-β expression often correlates with the malignancy of many cancers. In this study, we tried to unravel the mechanism of TGF-β downregulation-induced by using adenovirus expressing short hairpin RNA against transforming growth factor-β1 or β2 (TGF-β1/2). Notably, we found that TGF-β downregulation could increase the phospho-p38 and phospho-jnk expression, also decrease the survival molecule such as phospho-akt, phospho-src, phospho-stat3 and phospho-p65. Consistent with the increase of phosphor-p38 and p-jnk, the ASK1 phosphorylation (which means ASK1 activation) and reactive oxygen species(ros) production were also increased in response to TGF-β downregulation, whereas gene expression of Trx and GSTM1 known to be inhibitory binding proteins to ASK1 were decreased. In i

13 addition, interactions between GSTM1 and ASK1 or Trx and ASK1 were also decreased. This decrease in Trx and GSTM1 expression was likely to be related to the translocation of Smad complex proteins as a main mediator of canonical signalling pathway of TGF-β playing a tumor-promoting role by transcriptional activation of target genes such as Trx or GSTM1. However, ROS was not directly related to the transcriptional repression of Trx or GSTM1, while inducing dissociation of Trx and GSTM1 from ASK1 activation followed by tumor cell death. Morevoer, ASK1 inhibition with siask1 or overexpression of a dominant-negative kinase-inactive mutant of ASK1(ASK1-KM) rescued cell death. In addition, p38 MAPK/JNK activation was also inhibited by siask1 or ASK1-KM, suggesting that ASK1 signaling via p38 MAPK/JNK activation was the main pathway of adenovirus-expressing shtgf- β1 or 2 induced cell death. Taken together, our findings demonstrate that treatment with adenovirus expressing shrna of TGF-β1 or 2 can cause cell death via ASK1 activation, which was associated with the reduction of Trx and GSTM1 gene expression and dissociation of the Trx/GSTM1 from ASK1 Trx, ASK1-GSTM1 complexes Key words: TGF-β1, TGF-β2, ROS, ASK1, adenovirus, cell death ii

14 Study on the mechanism of cancer cell death induced by TGF-β1, TGF-β2 downregulation Zhezhu Han Department of Medical Science The Graduate School, Yonsei University (Directed by Professor Jae Jin Song) I. INTRODUCTION Cancer is one of the most common diseases worldwide. While North American populations are twice as likely to develop cancer than those in Asia, the death rate in Asia was twice as high as that in North America. 1 Several modalities currently exist to treat cancer, including surgery, chemotherapy and radiation therap. Surgical resection is often used to remove a cancer in its entirety, however, many tumors have the tendency to spread to adjacent areas. In the cases, patients typically undergo chemotherapy and radiotherapy, which have known side-effects. 2 As such, gene therapy could serve as a means to treat cancer without the adverse effect on patients. 3 Gene therapy is the delivery of nucleic acid polymers into a patient s 1

15 cells to treat disease. 4 The most common form of gene therapy uses DNA that encodes a functional, therapeutic gene to replace its endogenous mutated counterpart. The polymer molecule is packaged with viral or non-viral vectors for cellular uptake. For example, recombinant adenovirus can be grown to high titers and has a relatively high capacity for transgene insertion, usually without incorporation of viral DNA into the host cell genome. 5, 6 Moreover, the use of oncolytic adenovirus in gene therapy will not damage normal cells, but can be engineered to induce tumor-specific cell lysis. 5, 6, 7 During viral infection adenovirus virion particle to the cell surface occurs through binding of the fiber knob to the coxsackievirus B and adenovirus receptor (CAR). 6 Therefore, effective therapeutic gene delivery can be induced by using the 8, 9, 10 adenoviral vector construct without any further engineering. In addition, this vector can be used to transport various types of genes into 11, 12, 13 the cell, without discrimination. TGF-β, a secreted cytokine, plays a multi-faceted role in tumorigenesis. 14 Interestingly, it functions as a tumor suppressor by restraining cell proliferation and immortalization, while encouraging apoptosis. Alternatively, TGFβ can also act as a promoter of tumor metastasis, such as induction of epithelial-mesechymal transitinon (EMT), 2

16 cell adhesion, migration, invasion, chemoattraction, and tumor metastasis. 15, 16, 17, 18, 19, 20 Notably, some human tumors become resistant to the effects of TGF-β as a result of genetic and epigenetic changes, whereas others are subject to pro-oncogenic pathway activation such as MAPK, PI3K, Ras, and c-myc that can override any growth inhibitory 21, 22 signaling pathways. The TGF-β receptor is a heteromeric cell-surface complex comprised of specific Type I and II transmembrane serine/ threonine kinases, which is highly expressed by tumor cells. 23 Ligand-induced receptor activation induces a temporary interaction between the TβRI receptor and Smad2/3 subsequently stabilized by the FYE protein SARA. TβRI phosphorylates the C-terminals of Smad2/3, resulting in their dissociation from the receptor and Smad4 recruitment. The Smad2/3/4 complex then translocates into the nucleus and interacts with the promoter with the transcription factors with sequence-specific DNA binding to regulate gene expression. Smad-mediated gene expression is controlled by several intracellular signaling pathways, including the c-jun N-terminal kinase(jnk)/p38 MAP kinase and β-catenin/wnt signaling. 24, 25 TGFβ consists of three isoforms (TGFβ1/2/)3, each encoded by a 3

17 different genes. 26 Specifically, TGF-β1 regulates various immune responses depending on the cell type and development stage. In most cases, TGF-β1 is secreted by immune cells (or leukocytes). 27 Some T cells actions are inhibited by TGF-β1 released from the other T cells. 28 Likewise, TGF-β1 hinder the secretion of cytokines, such as interferon-γ(ifn-γ), tumor necrosis factor-alpha (TNF-α), and various interleukins(ils). Alternatively, TGF-β1 acts to attenuate B cell proliferation while promoting apoptosis. 29 TGF-β2 distinguishes itself through its suppressive effects on early interleukin-dependent T cell tumors. In the advanced cancer stage, TGF-β levels were significantly higher, especially as TGF-β2. As is revealed by earlier research, poorer prognosis accounts for the increased expression level of TGF-β1 and TGF-β2 proteins. 30, 31 In a more general context, TGF-β also regulates cell proliferation, differentiation, angiogenesis, and wound healing and regulatory T cell activity. 32, 33 Moreover, for some immune response of certain cell types, such as NK cells, dendritic cells, macrophage and T cells are inhibited by cancer cells with the help of TGF-β signaling. 34 Collectively, these lines of evidence support TGF-β as a cancer target and enhance anti-tumor immunity. In previous studies, we designed an adenovirus delivered TGF-β1 4

18 shrna and TGF-β2 shrna, to reduce TGF-β1/2expression, respectively. Antitumor effects were tested by adenovirus delivered TGF-β1 shrna and TGF-β2 shrna in various tumor cells, among the tumor cells with increased cell death the phospho-p38 and phospho-jnk expression were increased, also ROS production was increased. In addition, TGF-β signals via the conserved MAPK pathway including extracellular-related kinase 1/2 (ERK1/2 or p44/42 MAPK), c-jun N-terminal kinase (JNK) and p38 MAPK to regulate cell proliferation, differentiation, survival and apoptosis 35 MAPKs also respond to various forms of extracellular stress, such as cytokines ultraviolet irradiation, heat shock, and osmotic stress. 36 In response to various extracellular stimuli, such as TGF-β, intracellular signal transduction is activated. p38 MAPK can control gene expression to alter the cell growth, and apoptosis. For this reason, p38 MAPK has been considered a leading molecular target in cancer 37, 38 therapy. Apoptosis signal-regulating kinase 1(ASK1) is a mitogen-activated protein kinase kinase kinase (MAPKKK) that activates JNK and p38 by direct phosphorylation primarily in response to cytotoxic stressors such as tumor necrosis factor (TNF), Fas ligand, and reactive oxygen species (ROS) to accelerate apoptosis. 39, 40, 41, 42 It has been documented that the 5

19 mechanisms of MAPK stimulates apoptosis via Bcl-2 family proteins, and caspase family proteins in cancer cells. 43 ROS including the superoxide anion radical (O -. 2 ), singlet oxygen ( 1 O 2 ), hydrogen peroxide (H 2 O 2 ), and the highly reactive hydroxyl radical (. OH) are by products of oxygen metabolism. 44 ROS play a role in the central cellular process that is part of the development of a cancer cell, proliferation, apoptosis and senescence. 45 Thioredoxin (Trx) is expressed by all living organisms. A Trx-ASK1 complex is generated with the integration of Trx and ASK1. Such complex renders the expression of ASK1 protein inactive. 46 ROS induces the dissociation between Trx and ASK1, which leads to the activation of the ASK1/JNK signaling pathway and subsequent increase of apoptosis. 47, 48 Alternatively, Glutathione S-transferase Mu 1(GSTM1) interacts with the ASK1 N-terminals to enhance oxidative stress-induced ASK1-dependent apoptosis. 49 GSTM1/ASK1 complex is dissociated under oxidative stress, then cause the activation of ASK1. 50 In this research, we designed adenoviruses delivering TGF-β1 shrna or TGF-β2 shrna to reduce TGF-β1 or 2 expression and found that they can cause tumor cell death by inducing ASK1 activation and consequent p38 and JNK activation. The ASK1 activation was found to 6

20 be deeply related to both the reduction of Trx and GSTM1 gene expression and dissociation of Trx or GSTM1 from ASK1 Trx, ASK1-GSTM1 complexes. 7

21 II. MATERIALS AND METHODS 1. Cell culture A375, HPAC were cultured in Dulbecco's modified Eagle's medium (DMEM, HyClone, Logan, UT, USA) with 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA) and maintained in a 37 C humidified atmosphere containing 5% CO 2. The medium was changed every 2 3 days after transfection. 2. Plasmids and recombinant proteins HA-tagged ASK1 wild type was constructed in pcdna3.1 plasmid (Invitrogen, Carlsbad, CA). A kinase-inactive form of ASK1 (K709M) was introduced into wild type of ASK1 with the QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, SF, USA) using pcdna3-ha-ask1 as a template. The sense and antisense primer s were used 5 -gcaaccaagtcagaattgctattagggaaatcccagagagagac-3 and 5 -gtctctctctgggatttccc taatagcaattctgacttggttgc-3 for K709M. The small interfering RNA (sirna) against ASK1 and control sirna were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 3. Construction of adenoviral vectors Human TGFβ1 and TGFβ2 shrnas were generated with annealing 8

22 oligonucleotides subcloned into BamHI/HindⅢ-digested psp72δe3-u6 shuttle vector termed psp72δe3-u6-shtgfβ1, psp72δe3-u6-shtgfβ2, respectively. The vectors were linearized by XmnI digestion, and co-transformed into Escherichia.coli BJ5183 with SpeI-digested adenoviral vector (dl324-ix) for homologous recombination. Viruses were defined as follows. 4. Name of recombinant adenovirus Ad-NC: Ad-IX-ΔE1B, control virus Ad-shTGFβ1: Ad-IX-ΔE1B-ΔE3-U6-shTGFβ1, virus expressing shrna of human TGFβ1 Ad-shTGFβ2: Ad-IX-ΔE1B-ΔE3-U6-shTGFβ2, virus expressing shrna of human TGFβ2 5. MTS viability assay Cell viability was assessed with a CellTiter 96 Aqueous Assay kit (Promega, Madison, WI, USA) that contains a tetrazolium compound (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetraz olium, MTS) is bioreduced by metabolically active cells in the presence of an electron coupling reagent (phenazineethosulfate; PES). Assays were performed 48 hr after adenovirus infection with A375 or HPAC cells seeded in 96-well plates. Absorbance at 490 nm was used to measure cell viability. 9

23 6. Western blot analysis Cells were lysed in 1X Laemmli lysis buffer (62.5mM Tris, ph 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 0.002% bromophenol blue) and protein concentrations determined with BCA Protein Assay Kit (Thermo Scientific, Fremont, CA, USA). The protein samples were then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and electro transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were detected with anti-phoshoakt (pakt), anti-phosphosrc (psrc), anti-phosphostat3(pstat3), anti-phosphop65 (pp65), anti-smad2(smad2), anti-phosphosmad2 (psmad2), anti-ask1, anti-phosphoask1 (pask1), anti-smad3 (Smad3), anti-phosphosmad3 (psmad3), anti-phosphoerk (perk), anti-phoshop38 (pp38), anti-phosphojnk (pjnk), anti-p65, anti-erk, anti-akt, anti-stat3, anti-jnk, anti-src and anti-p38, which were purchased from Cell Signaling Technology (Danvers, MA, USA), anti-phosphohsp27(phsp27), anti-hsp27(hsp27), anti-trx(trx), anti-gstm1(gstm1), anti-ap1(ap1), anti-sp1(sp1), anti-smad4(smad4), anti-gapdh came from Santa Cruz Biotechnology (Dallas, TX, USA). Immunoreactive bands were visualized by chemi-luminescence or fluorescent imaging(syngene, Cambridge, UK). 7. Real-time polymerase chain reaction(rt-pcr) Total RNA was isolated from cells with standard Trizol (Life Technologies, Carlsbad, CA, USA)/chloroform extraction. RNA concentration was determined 10

24 with a Nanodrop 2000 (Thermo Scientific). RT-PCR was performed with the Power SYBR Green RNA-to-CT 1-Step Kit (Life Technologies) in reaction mixtures containing the reverse transcriptase enzyme mix, reverse transcription PCR mix, forward primer, reverse primer, RNA template and nuclease-free water. Human TGFβ1 cdna was amplified using the forward primer, 5'- TTGCTTCAGCTCCACAGAGA -3', and the reverse primer: 5'- TGGTTGTAGAGGGCAAGGAC -3'. Human TGFβ2 cdna was amplified using the forward primer, 5'-GTGAATGGCTCTCCTTCGAC-3', and the reverse primer: 5'-CCTCGAGCTCTTCGCTTTTA-3'. Human β-actin was amplified by using the forward primer, 5'-GGCTGTATTCCCCTCCATCG-3', and the reverse primer: 5'-CCAGTTGGTAACAATGCCATGT-3'. 8. Clonogenic assay A375 and HPAC cells were plated in six-well plates at cells/well and infected with adenovirus (Ad-NC, Ad-shTGFβ1, Ad-shTGFβ2). Cells were then trypsinized and plated 48 hr later to or cells/well in six-well plates and monitored daily by microscopy. Once cells formed colonies, the plate were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet. 9. Measurement of intracellular level of ROS 11

25 Intracellular ROS was assessed using the ROS-specific probe 2-7 -diclorofluorescein diacetate (DCF-DA, Sigma-Aldrich, St. Louis, MO, USA). Cells were incubated with 20 μm DCF-DA for 1 hr and fluorescence signals were obtained with a fluorescence microscope. 10. Enzyme-linked immunosorbent assay (ELISA) Cells were plated in six-well plates at cells/well and supernatants collected 48 hr later to assess the levels of secreted TGF-β1 or TGF-β2 with a commercial ELISA kit according to the manufacturer s instructions (R&D Systems, Minneapolis, MN, USA). 11. Immunopricipitation(IP) Immunopricipitation were performed at 4 C unless otherwise indicated, using a Pierce spin column that can be capped and plugged with a bottom plug for incubation or unplugged to remove the supernatant by centrifugation at 1000 g for 1 min. Antibody binding to protein A/G agarose was performed as described in the Pierce Crosslink Immunoprecipitation kit with a slight modification. Briefly, protein A/G agarose slurry (20 µl) was washed twice with 200 µl PBS buffer, and then incubated in 10 µl Trx, GSTM1, ASK1, Ap1, Sp1, Smad4 antibody diluted with 90 µl PBS for 30 min at 25 C on a mixer. In parallel, 100 µl of mouse and rabbit serum or anti-mouse and anti-rabbit IgG 12

26 peroxidase secondary antibody served as a negative control. The supernatant was subsequently discarded and the beads washed three times with 300 µl PBS, followed by incubation with 50 µl 2.5mM DSS solution at 25 C for min on a mixer. The beads were then washed three times with 50 µl 100 mm glycine (ph 2.8), twice with 300 µl 1% NP-40 in PBS, and then once with 300 µl PBS. The antibody-cross-linked beads were incubated overnight at 4 C with 600 µl A375 or HPAC cell lysate pre-cleared with control agarose resin (Pierce, Waltham, MA, USA) for 1 hr on a shaker. After removing supernatant (flow-through) and washing with 300 µl washing buffer (25 mm Tris, 150 mm NaCl, 1 mm EDTA, 1% NP-40, 5% glycerol, ph 7.4) three times, the immunoprecipitates were eluted with 60 µl Elution buffer and boiled at 100 C for 10 min. The eluate was then subjected to western blotting. 12. Chromatin immunoprecipitation(chip) assay ChIP assays were performed with a kit from Thermo Scientific (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer s instructions. Briefly, treated cells were washed with PBS, cross-linked with 1% formaldehyde for 10 min, rinsed with ice-cold PBS, collected into PBS containing protease inhibitors, and then resuspended in lysis buffer (1% SDS, 10 mm EDTA, 50 mm Tris at ph 8.1 with 1% protease inhibitor cocktails). The cells were sonicated to produce bp DNA fragments, and then 13

27 centrifuge to remove insoluble material at 9000 g for 5 min. DNA immunoprecipitation was performed with the indicated antibodies overnight at 4ºC. After centrifugation to transfer the supernatant to a new 1.5 ml tube, 20μL beads were added to each IP incubated for 2 hr at 4 ºC, and centrifuged. The beads were washed twice with Wash Buffer 1, once with Wash Buffer 2, once with 150μL 1X IP Elution Buffer, and incubated at 65 ºC for 30 min, The solutions were then aliquoted into tubes containing NaCl and Proteinase K, incubated at 65 ºC for 1.5 hr. Subsequently, 750μL of DNA Binding Buffer was added to each tube, mixed, and then 500μL of each sample was transferred to a DNA Clean-Up Column for purification. The resulting DNA was subjected to RT-PCR with primers specific for the human Trx promoter (5 -TCCAGGAGTCTGCCTCTGTTAG-3 and 5 -CTGCTGGA GTCTGACGAGCG-3 ), GSTM1 promoter (5 -TAGGATCTGGCTGGTGT CTC-3 and 5 -GTGCGGATTCCGCAGACAGG-3 ). PCR reactions were run with Absolute qpcr SYBR Green Fluorescein Mix (Thermo Scientific) with an initial denaturation at 95 C for 15min, followed by 40cycles of denaturation at 95 C for 15 s and annealing at 62 C for 1 min. 13. Animal study To generate a xenograft tumor model, A375 and HPAC tumor cells were injected into the subcutaneous abdominal region of male BALB/c athymic 14

28 nude mice. When the tumors reached an average size of mm 3, the nude mice received intratumoral injections of plaque forming units (pfu) of one of three defective adenoviruses diluted in 50 μl PBS or PBS alone. The defective adenoviruses used were defective control adenovirus (Ad-NC), TGFβ1/TGFβ2 shrna-expressing defective adenovirus (Ad-shTGFβ1/TGFβ2. Intratumoral injection was repeated every other day for a total of three injections. Regression of tumor growth was assessed by taking measurements of the length (L) and width (W) of the tumor. Tumor volume was calculated using the following formula: volume = 0.52 * L * W Immunohistochemistry (IHC) Tumor tissues were extracted, fixed for 24 hr in 10% formaldehyde, and paraffin embedded for immunohistochemical (IHC) staining. IHC staining was performed as follows. Tissue section slides were deparaffinized twice with xylene for 10 min each and slides were rehydrated using a graded alcohol series. After removing endogenous peroxidases using 0.1% H2O2, slides were washed three times with PBS. Antigen retrieval was performed using 10 mm citrate buffer (ph 6.0) (DAKO, Glostrup, Denmark) and a microwave oven. Tissues were permeabilized with 0.5% PBX (0.5% Triton X-100 in PBS) for 30 min. After blocking for 1 hr with 5% BSA, the primary antibody was added and incubated overnight at 4 C. Primary Antibody Enhancer (Thermo Fisher 15

29 Scientific, Waltham, MA, USA) and HRP Polymer (Thermo Scientific) were used for signal amplification. To develop the colored product, a mixture of DAB (3,3 -diaminobenzidine) Plus Chromogen and DAB Plus Substrate (Thermo Fisher Scientific) was added for 5 min. After washing with PBS, 20% hematoxylin counterstain was added for 2 5 min to stain the nuclei. Finally, tissue slides were dehydrated in a graded alcohol series. After clearing twice in xylene, tissues slides were coverslipped with mounting media (xylene:mount = 1:1) for microscopy. 15. Statistical analysis The data were expressed as mean ±standard error (SE). Statistical comparison was made using Graph Pad (Systat Software Inc). P values less than 0.05 were considered statistically significant (*, P<0.05; **, P<0.01;***, P<0.001). 16

30 III. RESULTS 1. TGF-β1 or 2 expression in cells after infection with an adenovirus expressing shtgf-β1 or 2 Almost all human tumors overexpress TGF-β, which contributes to the induction of tumor cell invasion and metastasis. 51 Accordingly, in this study shrnas against TGF-β were used as therapeutic agents. It has been known that TGF-β1 and TGF-β2 are highly expressed in cancer cells, whereas TGF-β3 is rarely expressed. To decrease the expression of TGF-β1 or TGF-β2 protein, recombinant adenoviruses were constructed containing the shrna of TGF-β1 or TGF-β2. The infection efficiency of adenovirus type 5(AAV5) was examined in human cells before confirming the repression of TGF-β1/2 mrna and protein. We then examined the knockdown efficacy of adenoviruses expressing shtgf-β1 or 2 with various MOIs (10, 50 and 100) in human A375 cells using RT-PCR and ELISA assays were subsequently performed to determine whether the viruses decreased TGF-β1 or 2 expression at the mrna or protein level. TGF-β1 mrna was decreased by 20% at only 10 MOI and TGF-β1 mrna was suppressed by 80% at 100 MOI, also TGF-β2 mrna was decreased by 20% at only 10 MOI and TGF-β2 mrna was suppressed by 75% at 100 MOI in A375 cells (Figure 1A), suggesting that the knockdown efficacy correlated with viral MOI. Similar results were also observed with TGF-β1 or 2 protein expression (Figure 1B). 17

31 (A) (B) Figure 1. Downregulation of human transforming growth factor (htgf)-β1 or 2 short hairpin RNA(shRNA). Cancer cells (human A375 cells) were infected with adenovirus-expressing shrna targeting human TGF-β1(Ad-shTGF-β1), human TGF-β2(Ad-shTGF-β2) or scrambled DNA (Ad-NC). TGF-β1 or 2 mrna(a) and protein levels(b) were assayed by 18

32 quantitative real-time polymerase chain reaction(qrt-pcr) and enzyme-linked immunosorbent assay(elisa), respectively. MOI, multiplicity of infection; NC, negative control. 2. Adenovirus expressing shrna of TGF-β1 or 2 can induce several signaling pathways change in melanoma and pancreatic cancer cell lines TGF-β is a key signaling molecule overexpressed by many cancers. Therefore, we examined the effect of TGF-β downregulation on various pathways in A375 and HPAC cell lines including p38, HSP27, p65, Src, Akt, Stat3, JNK, Smad and ERK by western blotting. Notably, we observed that activity of phospho-p38 (p-p38) and phospho-jnk were increased by Adenovirus expressing shrna of TGF-β1 or 2 infection. Also the survival molecules phospho-akt, phosphor-src, phospho-p65, phospho-stat3 were decreased (Figure 2A). However, in pancreatic normal cells the various key signaling pathway molecules, including p38, HSP27, p65, Src, Akt, Stat3, JNK, Smad and ERK expression were not changed (Figure 2B). Next, in order to examine whether shtgfβ1 or 2 adenovirus inhibits cancer cell survival and proliferation, MTT assays and clonogenic assays were performed, which can measure short-term and long-term cancer cell survival. The MTT assay results showed that shtgfβ1 or 2 adenovirus infection in A375, HPAC cells induced significant reduction of cell survival (Figure 2C). The clonogenic assay results indicated that clonogenic assay survival decreased in both melanoma and 19

33 pancreatic cancer cells when infected with shtgfβ1 or 2 adenovirus (Figure 2D). (A) (B) 20

34 (C) A375 HPAC (D) Figure 2. Effect of adenovirus-expressing shtgf-β1 or 2 in melanoma and pancreatic cancer cell lines. (A) A375 and HPAC cell lines were treated using adenovirus-expressing shtgf-β1/2 at 100MOI respectively. After 48 hr, the expression of p-p38, p38, p-hsp27, HSP27, p-erk, p-src, p-p65, p-jnk, p-stat3 and GAPDH were detected via western blot analysis. (B) Pancreatic 21

35 normal cell lines were treated using adenovirus-expressing shtgf-β1/2 at 100MOI respectively. After 48 hr, the expression of p-p38, p-akt, p-hsp27, HSP27, p-erk, p-src, p-p65, p-jnk, p-stat3 and GAPDH were detected via western blot analysis. (C) A375 and HPAC cells were treated with adenovirus-expressing shtgf-β1/2. After 48 hr, cell viability was tested via a MTS viability assay. Error bars represent the standard error from three independent experiments. (D) A375 and HPAC cells were treated with adenovirus-expressing shtgf-β1/2 for 48 hr, and incubated for an additional 14 days for clonogenic assays. 3. No off-targeting effect of adenovirus-expressing shtgf-β1 or 2 in melanoma cancer cell lines Despite the recent advances in gene-engineering technologies. 52 RNAi remains one of the most versatile and powerful tools to stydy and manipulate gene expression in eukaryotic organisms. 53 One specific variant is shrna that consists of a stem composed of an antisense (or guide) strand that is complementary to a target mrna and a sense (or passenger) strand that ideally is inert and merely provides structure to complete the double-stranded molecule. In addition to binding their designated target, shrna antisense strands can also recognize and degrade other mrnas with similar complementarity, resulting in off-target effects. In order to find out if there have off-targeting effects while infection with adenovirus-expressing shtgf-β1 or 2, A375 cells were infected 22

36 with one shrna and examined by western blotting after recombinant TGFβ1 treatment. We can see that the p-src, p-p65, p-stat3, p-hsp27, p-p38 expression were clearly recoverd from treatment with recombinant TGFβ1 protein (Figure 3A). Also morphology shows a similar result with western blot data (Figure 3B). Therefore, these results suggest that no off-targeting effects were associated with adenovirus-expressing shtgf-β1 or 2 treatment. (A) 23

37 (B) Figure 3. No off-targeting effect of adenovirus-expressing shtgf-β1 or 2 in melanoma cancer cell lines. (A) A375 cell lines were infected with adenovirus-expressing shtgf-β1 at 100MOI with or without of recombinant TGF-β1 750ng/ml for time-dependent, respectively. After 48 hr, the expression of p-p38, p-akt, p-hsp27, p-erk, p-src, p-p65, p-stat3 and GAPDH were detected via western blot analysis. (B) A375 cell lines were infected with adenovirus-expressing shtgf-β1 at 100MOI with or without of recombinant TGF-β1 750ng/ml for time-dependent, respectively. After 48 hr, morphological changes were observed by using microscopy. 4. Increased ROS generation was induced by adenovirus expressing shrna of TGF-β1 or 2 24

38 ROS has been reported to be related to JNK and p38 pathways in many studies. 54 Thus, we assessed ROS generation by adenovirus expressing shrna of TGF-β1 or 2 infection. As a result, ROS was increasingly generated after 48 hr of adenovirus expressing shrna of TGF-β1 or 2 infection in A375, HPAC cells (Figure 4A). whereas little amount of ROS generation was observed in pancreatic normal cells (Figure 4B). (A) 25

39 (B) Figure 4. ROS generation was induced by shtgf-β1 and shtgf-β2 expressing adenoviruses. (A) A375 and HPAC cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100MOI, respectively after 48 hr, incubation with DCF-DA (20 μm) for 1 hr. (B) Pancreatic normal cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100MOI respectively after 48 hr, incubation with DCF-DA (20 μm) for 1 hr. 5. Effects of NAC on cell growth and apoptosis in Adenovirus expressing shrna of TGF-β1 or 2 treated melanoma and pancreatic cancer cells N-acetylcysteine (NAC) is an aminothiol and synthetic precursor of intracellular cysteine and GSH and a strong antioxidant widely used to investigate the role of ROS in apoptosis. 55 The effect of NAC on cell growth and apoptosis after adenovirus expressing shrna of TGF-β1 or 2 infection treated melanoma and pancreatic cancer cells were then examined. As a result, 26

40 the ROS production was significantly reduced by NAC treatment, however the cell death still remained(figure 5A, 5B), which suggest that the cell death induced by Adenovirus expressing shrna of TGF-β1 or 2 treatment were correlated with survival molecule downregulation and ROS produciton. (A) (B) Figure 5. Effects of NAC treatment with Adenovirus expressing shrna of TGF-β1 or 2 in melanoma and pancreatic cancer cells. (A) A375 cell lines 27

41 were infected with adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 6 hr, infected cells were treated with NAC (10 mm) for 42 hr, then incubated with DCF-DA (20 μm) for 1 hr. (B) HPAC cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 6 hr, infected cells were treated with NAC (10 mm) for 42 hr, then incubated with DCF-DA (20 μm) for 1 hr. 6. Dissociation of Trx from ASK1 Trx complexes induced by Adenovirus expressing shrna of TGF-β1 or 2 infection Trx and GSTM1 have been identified as binding proteins of ASK1. Trx has been shown to inhibit signal cascades downstream of ASK1 in a redox-dependent manner. 56 ROS such as hydrogen peroxide which was produced by adenovirus expressing shrna of TGF-β1 or 2 infection is able to dissociate Trx or GSTM1 from ASK1. Both cellular protein levels of Trx and GSTM1 expression (Figure 6A) and mrna level of Trx and GSTM1 expression (Figure 6B) were decreased by shtgfβ1 or 2 adenovirus infection. Moreover, interaction between endogenous Trx and ASK1 (Figure 6C) or interaction between endogenous GSTM1 and ASK1 (Figure 6D) was decreased by adenovirus expressing shrna of TGF-β1 or 2 infection. These results suggest that the increased ASK1 activity was correlated with both of reduction of Trx and GSTM1 expression and dissociation of Trx and GSTM1 from ASK1 Trx, ASK1-GSTM1 complexes, respectively. 28

42 (A) (B) 29

43 (C) (D) Figure 6. Effects of NAC treatment with Adenovirus expressing shrna of TGF-β1 or 2 in melanoma and pancreatic cancer cells. (A) A375 and HPAC cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 48 hr, the expression of p-ask1, ASK1, Trx, GSTM1 and GAPDH were detected by western blot analysis. (B) A375 and HPAC cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 48 hr, the expressions of Trx and GSTM1 mrna level were assayed by quantitative real-time polymerase chain reaction (qrt-pcr). (C) A375 cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 48 hr, lysates were then subjected to 30

44 immunoprecipitation with using an anti Trx antibody to identify changes in complex formation. (D) A375 cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 48 hr, lysates were then subjected to immunoprecipitation with using an anti GSTM1 antibody to identify changes in complex formation. 7. Regulation of Trx, GSTM1 promoter activity, Ap1, Sp1 and Smad molecule expression by TGFβ While, Trx promoter contains several consensus Ap1 and Sp1 binding sites, whereas the GSTM1 promoter contains only Ap1 binding sites. TGFβ regulates gene transcription primarily through the intracellular Smad signaling cascade, which is initiated by binding of the TGFβ ligand to heteromeric complexes of specific type II (TβR-II) and type I (TβR-I) kinase receptors. 57 Treatment with adenovirus expressing shrna of TGF-β1 or 2, however, Trx and GSTM1 promoter activity were decreased (Figure 7A), and the Ap1 and Sp1 protein levels were also reduced by adenovirus expressing shrna of TGF-β1 or 2 infection (Figure 7B). SMADs are intracellular proteins that transduce extracellular signals from TGF β ligands to the nucleus where they activate downstream gene transcription. 57 While infection with adenovirus expressing shrna of TGF-β1 or 2, the expression of p-smad2 and p-smad3 were decreased (Figure 7C). Also, the physical interaction between Ap1 or Sp1 and the Smad proteins were decreased (Figure 7D). This suggests that decreased 31

45 level of Sp1, Ap1 gene expression and reduction of the interaction between Ap1 or Sp1 and the Smad proteins played a causative role for the reduction of Trx and GSTM1 gene expression. (A) A375 HPAC (B) 32

46 (C) (D) Figure 7. Regulation of Trx, GSTM1 promoter activity by TGFβ. (A) A375 and HPAC cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 48 hr, Trx, GSTM1 promoter activity were analysed by Chip assays. (B) A375 and HPAC cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 48 hr, the expression of Ap1, Sp1 and GAPDH were detected by western blot analysis. (C) Also the p-smad2, Smad2, p-smad3, Smad3, Smad4 and GAPDH were detected by western blot analysis. (D) A375 cell lines were infected with 33

47 adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 48 hr, lysates were then subjected to immunoprecipitation with using an anti Ap1 and anti-sp1 antibody to identify changes in complex formation. 8. No effect of expressing shrna of TGF-β1 or 2 adenovirus treatment induced ROS on Trx, GSTM1 expression Even though ROS can dissociate Trx or GSTM1 from ASK1 Trx, ASK1-GSTM1 complexes, it remains unclear whether it also regulates Trx and GSTM1 gene expression. We assessed the impact of ROS on Trx and GSTM1 expression. NAC was combined with adenovirus expressing shrna of TGF-β1 or 2. Interestingly, Trx and GSTM1 expressions were not likely to be changed much by NAC (Figure 8A, B, C). This suggests that ROS is involved in the dissociation of Trx or GSTM1 from ASK1 Trx, ASK1-GSTM1 complexes, but not Trx and GSTM1 gene expression. (A) 34

48 (B) A375 (C) HPAC Figure 8. Effects of NAC on Trx, GSTM1 expression with expressing shhtgf-β1 or 2 adenovirus infection in melanoma and pancreatic cancer cells. (A) A375 and HPAC cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 6 hr, infected cells were treated with NAC (10 mm) for 42 hr. Then the p-smad2, p-smad3, Trx, GSTM1 and GAPDH were detected by western blot analysis. (B), (C) A375 and HPAC cell lines were infected with adenovirus-expressing shtgf-β1 or 2 at 100 MOI, respectively. After 6 hr, infected cells were treated with NAC (10 mm) for 42 hr. Then the expressions of Trx and GSTM1 mrna level were assayed by 35

49 quantitative real-time polymerase chain reaction (qrt-pcr). 9. ASK1 mediates TGFβ induced cell death via p38 MAPK/JNK activation As MAPKs are activated during adenovirus-expressing shtgf-β1 or 2-induced apoptosis of A375 and HPAC cells, we wanted to investigate the possible role of ASK1 in regulating p38 MAPK/JNK activation and whether inhibition of ASK1 activity would result in a corresponding inhibition of cell death. A375 and HPAC cells stably transfected with siask1 were used, and combined with infection of adenovirus-expressing shtgf-β1 or 2. As shown in figure 9A, downregulation of ASK1 with siask1 increased the viability of adenovirus-expressing shtgf-β1 or 2-infected cells, and the morphology of cells undergoing cell death seemed to be recovered (Figure 9B, 9C). The p38 MAPK/JNK activation were also inhibited by siask1 (Figure 9D). Futher, overexpression of a dominant-negative kinase-inactive mutant of ASK1(ASK1 -KM) shows an identical pattern to that of siask1(figure 9E, 9F, 9G, 9H), suggesting that ASK1 signaling cascade via p38 MAPK/JNK activation were likely the main pathway of adenovirus-expressing shtgf-β1 or 2-induced cell death. 36

50 (A) A375 HPAC (B) 37

51 (C) (D) 38

52 (E) A375 HPAC (F) 39

53 (G) (H) 40

54 Figure 9. ASK1 mediates TGFβ induced cell death via p38 MAPK/JNK activation. (A) A375 and HPAC cells were infected with adenovirus-expressing shtgf-β1 or 2 at 100MOI and transfected with siask1 (200nM) subsequently. After 48 hr, cell viability was tested by an MTS viability assay. Error bars represent the standard error from three independent experiments. (B), (C) A375 and HPAC cells were infected with adenovirus-expressing shtgf-β1 or 2 at 100MOI and transfected with siask1 (200nM) subsequently. After 48 hr, morphological changes were observed using microscopy. (D) A375 and HPAC cells were infected with adenovirus-expressing shtgf-β1 or 2 at 100MOI and transfected with siask1 (200nM) subsequently. After 48 hr, the expression of p-p38, p-akt, p-hsp27, HSP27, p-erk, p-src, p-p65, p-jnk, p-stat3 and GAPDH were detected by western blot analysis. (E) A375 and HPAC cells were infected with adenovirus-expressing shtgf-β1 or 2 at 100MOI and transfected with ASK1-KM 1μg subsequently. After 48 hr, cell viability was tested by an MTS viability assay. Error bars represent the standard error from three independent experiments. (F), (G) A375 and HPAC cells were infected with adenovirus-expressing shtgf-β1 or 2 at 100MOI and transfected with ASK1-KM 1μg subsequently. After 48 hr, morphological changes were observed using microscopy. (H) A375 and HPAC cells were infected with adenovirus-expressing shtgf-β1 or 2 at 100MOI and transfected with ASK1-KM 1μg subsequently. After 48 hr, the expression of p-p38, p-akt, p-hsp27, HSP27, p-erk, p-src, p-p65, p-jnk, p-stat3 and GAPDH were 41

55 detected by western blot analysis. 10. Enhanced anti-tumor effect induced by adenovirus expressing shtgf-β1 or 2 After a series of in vitro experiments, we confirmed that ASK1 mediated p38 MAPK/JNK activation was likely responsible for adenovirus-expressing shtgf-β1 or 2-induced cell death. Subsequently, we designed an in vivo experiment in xenograft animal models to confirm the anti-tumor effect of adenovirus-expressing shtgf-β1 or 2. Our results showed that treatment with adenovirus-expressing shtgf-β1 or 2 increased anti-tumor abilities in comparison to PBS or negative control, and TGF-β1 downregulation was better in tumor regression than TGF-β2 downregulation (Figure 10A). The result of immunohistochemical analysis showed that TGF-β1 or 2 expression was reduced by treatment with adenovirus-expressing shtgf-β1 or 2 compared with PBS and NC virus treated tumor tissues (Figure 10B). As shown in ex vivo experiments, we confirmed that adenovirus-expressing shtgf-β1 or 2 treatment could increase the anti-tumor effect. Therefore, TGF-β in various tumor cells could be an attractive target for the anti-tumor therapy. 42

56 (A) A375 HPAC 43

57 (B) Figure 10. Anti-tumor effect of adenovirus expressing shtgfβ1 or 2 in Xenograft animal models. (A) BALB/c nude mice were injected with cells/100 μl of A375 and HPAC cells. Seven days after the injection of tumor 44

58 cells, BALB/c nude tumor-bearing mice were treated with intratumoral injections of PFU/50 μl of PBS, Ad-NC, Ad- shtgf-β1, Ad- shtgf-β2 virus every other day for a total of 3 injection. (B) Tumors were collected day 11 for histological analysis. Paraffin-embedded sections of tumor tissue were stained with anti-adenovirus type 5(top row, original magnification: 200), anti-tgf-β1 (second row, original magnification: 200), and anti-tgf-β2 (third row, original magnification: 200) antibodies. 45

59 IV. DISCUSSION In many cancers, the expression of TGF-β isoforms were increased. For example, high levels of TGF-β1 have been detected in the gastric cancer patients. 58 The expression levels of TGF-β1 and TGF-β2 are also increased markedly in hepatocellular carcinoma (HCC). 59 Overexpression of TGF-β2 in cholangiocarcinoma promotes tumor cell proliferation. 60 In addition, the overexpression of TGF-β contributes significantly to the development of pancreatic cancer. 61 These results suggest that the major active isoform of TGF-β may be different depending on cancer cell types. In this study, shrna expressed in viral vector was used to suppress the expression of TGF-β1 or TGF-β2. A strong inhibition of tumor growth and survival was expected to follow the suppression of TGF-β1 or TGF-β2. Then, we showed the effect of shrna of TGF-β1 was stronger than that of shrna of TGF-β2 (Figure 2, 6, 7). When the expression of TGF-β1 or TGF-β2 was decreased, ROS generation was increased and the patterns of signaling molecules were changed. And sequentially, Trx and GSTM1 gene expression were decreased, and dissociation of Trx or GSTM1 from ASK1 Trx, ASK1-GSTM1 complexes were increased. Intriguingly, from these results, we found that ASK1 activation induced by TGF-β downregulation was proceeded by two different separate pathways: One is through decreased gene expression of ASK1-inhibitory binding proteins, and the other is through ROS generation for the dissociation of ASK1-inhibitory 46

60 binding proteins. However, the underlying mechanism of how TGF-β downregulation could induce ROS generation was not yet fully understood. Under the context of physiological/pathophusiological settings, MAPKs are of vital importance to the life or death for a cell. 62 It is proved that the activation of p38 MAPK/JNK results in apoptosis. 63 As is mentioned before, ASK1 belongs to the mitogen-activated protein kinase kinase kinase family, which is sensitive to different stimuli. 64 A TGF-β protein touches a receptor on the cell surface, which directs some relevant SMAD protein to activate, marks the start of signaling process. A protein complex comes into existence when SMAD proteins attaches to the SMAD4 protein. After the combination, the complex transfer to cell nucleus, in which it binds to specific areas of DNA, such as Trx promoter region of Ap1 and Sp1, and then regulate this genes expression. However, silencing TGFβ1 or 2 can reduce this interaction, also decrese the Ap1 and Sp1 expression, so that the Trx expression was decreased (Figure 7). These results suggest that ASK1 signaling cascade via p38 MAPK/JNK activation were likely the main pathway of adenovirus-expressing shtgf-β1 or 2-induced cell death. While with the downregulation of TGF-β1, p-akt expression was decreased. As is well known that Akt was involved in cellular survival pathways, by inhibiting apoptotic processes. TAK1 is a member of the MAPKKK family and is activated by various cytokines, including TGF-β family ligands. 65, 66 Several recent stydies show that TAK1 activation is required to induce Akt activation, and the inhibition of TAK1 reduces the activation of 47

61 Akt kinase. 67 Unfortunately, however, the influence for cell death by reduction of Akt expression after downregulation of TGF-β1 needs to be further elucidated. Taken all together, we demonstrate that treatment with adenovirus expressing shrna of TGF-β1 or 2 can cause various cell death, which was caused by ASK1 activation followed by p38 and JNK activation. ASK1 activation was also related to the reduction of Trx and GSTM1 gene expression and dissociation of Trx or GSTM1 from ASK1 Trx, ASK1-GSTM1 complexes. And the effect of shrna of TGF-β1 was stronger than that of TGF-β2 (Figure 11). 48

62 Figure 11. Schematic diagram of determination of cancer cell death by TGF-β downregulation. TGF-β1 or 2 downregulation can cause both ROS production and reduction of Smad complex (phospho-smad2, 3 with Smad4) that translocates to the nucleus to bind to gene promoters. ROS can dissociate Trx or GSTM1 from ASK1 Trx, ASK1-GSTM1 complexes, which induces ASK1 activation. ASK1 activation is also related to the reduction of Trx and GSTM1 gene expression, which results from decreased transcriptional activity of Smad complex. Conclusively, cancer cell death is caused by ASK1 activation followed by p38 and JNK activation. 49

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

법학박사학위논문 실손의료보험연구 2018 년 8 월 서울대학교대학원 법과대학보험법전공 박성민

법학박사학위논문 실손의료보험연구 2018 년 8 월 서울대학교대학원 법과대학보험법전공 박성민 저작자표시 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 귀하는, 이저작물의재이용이나배포의경우, 이저작물에적용된이용허락조건을명확하게나타내어야합니다.

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

- i - - ii - - iii - - iv - - v - - vi - - 1 - - 2 - - 3 - 1) 통계청고시제 2010-150 호 (2010.7.6 개정, 2011.1.1 시행 ) - 4 - 요양급여의적용기준및방법에관한세부사항에따른골밀도검사기준 (2007 년 11 월 1 일시행 ) - 5 - - 6 - - 7 - - 8 - - 9 - - 10 -

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

문학석사학위논문 존밀링턴싱과이효석의 세계주의비교 로컬 을중심으로 년 월 서울대학교대학원 협동과정비교문학 이유경

문학석사학위논문 존밀링턴싱과이효석의 세계주의비교 로컬 을중심으로 년 월 서울대학교대학원 협동과정비교문학 이유경 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

l l l l l l l l l Lee, Geon Kook None This project was designed to establish the Tumor Bank of National Cancer Center in 2000. From the first tumor sample in 2000, the total of tumor and tumor-related

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

행정학석사학위논문 공공기관기관장의전문성이 조직의성과에미치는영향 년 월 서울대학교행정대학원 행정학과행정학전공 유진아

행정학석사학위논문 공공기관기관장의전문성이 조직의성과에미치는영향 년 월 서울대학교행정대학원 행정학과행정학전공 유진아 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee University College of Medicine & Hospital E mail : ycell2@yahoo.co.kr Abstract

More information

Can032.hwp

Can032.hwp Chromosomal Alterations in Hepatocellular Carcinoma Cell Lines Detected by Comparative Genomic Hybridization Sang Jin Park 1, Mahn Joon Ha, Ph.D. 1, Hugh Chul Kim, M.D. 2 and Hyon Ju Kim, M.D. 1 1 Laboratory

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

MHC T cell Receptor Antigen Antigen-presenting cell Antigen-reactive T cell CD28 B7 Activation (proliferation Cytokine production Cytotoxicity) Antigen-presenting cell Antigen-reactive T cell Dormant State

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원

저작자표시 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원 저작자표시 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 동일조건변경허락. 귀하가이저작물을개작, 변형또는가공했을경우에는, 이저작물과동일한이용허락조건하에서만배포할수있습니다.

More information

歯1.PDF

歯1.PDF 200176 .,.,.,. 5... 1/2. /. / 2. . 293.33 (54.32%), 65.54(12.13%), / 53.80(9.96%), 25.60(4.74%), 5.22(0.97%). / 3 S (1997)14.59% (1971) 10%, (1977).5%~11.5%, (1986)

More information

저작자표시 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니

저작자표시 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니 저작자표시 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 귀하는, 이저작물의재이용이나배포의경우, 이저작물에적용된이용허락조건을명확하게나타내어야합니다.

More information

저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 동일조건변경허락. 귀하가이저작물을개작, 변형또는가공했을경우에는,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

Precipitation prediction of numerical analysis for Mg-Al alloys

Precipitation prediction of numerical analysis for Mg-Al alloys 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

농학석사학위논문 폴리페닐렌설파이드복합재료의기계적및열적 특성에영향을미치는유리섬유 환원된 그래핀옥사이드복합보강재에관한연구 The combined effect of glass fiber/reduced graphene oxide reinforcement on the mecha

농학석사학위논문 폴리페닐렌설파이드복합재료의기계적및열적 특성에영향을미치는유리섬유 환원된 그래핀옥사이드복합보강재에관한연구 The combined effect of glass fiber/reduced graphene oxide reinforcement on the mecha 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 동일조건변경허락. 귀하가이저작물을개작, 변형또는가공했을경우에는, 이저작물과동일한이용허락조건하에서만배포할수있습니다.

More information

경영학석사학위논문 투자발전경로이론의가설검증 - 한국사례의패널데이타분석 년 8 월 서울대학교대학원 경영학과국제경영학전공 김주형

경영학석사학위논문 투자발전경로이론의가설검증 - 한국사례의패널데이타분석 년 8 월 서울대학교대학원 경영학과국제경영학전공 김주형 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물

저작자표시 - 비영리 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물 저작자표시 - 비영리 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 귀하는, 이저작물의재이용이나배포의경우, 이저작물에적용된이용허락조건을명확하게나타내어야합니다.

More information

#Ȳ¿ë¼®

#Ȳ¿ë¼® http://www.kbc.go.kr/ A B yk u δ = 2u k 1 = yk u = 0. 659 2nu k = 1 k k 1 n yk k Abstract Web Repertoire and Concentration Rate : Analysing Web Traffic Data Yong - Suk Hwang (Research

More information

γ

γ 경락경혈학회지 Vol.27, No.1, pp.87 106, 2010 Journal of Meridian & Acupoint Dept. of 1 Meridian & Acupoint, 3 Acupuncture & Moxibustion, College of Oriental Medicine, Daejeon University 2 Division of Clinical

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

한국성인에서초기황반변성질환과 연관된위험요인연구

한국성인에서초기황반변성질환과 연관된위험요인연구 한국성인에서초기황반변성질환과 연관된위험요인연구 한국성인에서초기황반변성질환과 연관된위험요인연구 - - i - - i - - ii - - iii - - iv - χ - v - - vi - - 1 - - 2 - - 3 - - 4 - 그림 1. 연구대상자선정도표 - 5 - - 6 - - 7 - - 8 - 그림 2. 연구의틀 χ - 9 - - 10 - - 11 -

More information

i

i 저작자표시 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 귀하는, 이저작물의재이용이나배포의경우, 이저작물에적용된이용허락조건을명확하게나타내어야합니다.

More information

Δ Epidermal growth factor receptor (EGFR) is well established target for cancer treatment and EGFR tyrosine kinase (TK) inhibitors such as gefinitib and elotinib have been developed as anti-cancer drugs.

More information

저작자표시 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우, 이저작물에적용된이용허락조건을명확하게나타내어야합니다.

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

기관고유연구사업결과보고

기관고유연구사업결과보고 기관고유연구사업결과보고 작성요령 2001 ~ 2004 2005 ~ 2007 2008 ~ 2010 2001 ~ 2004 2005 ~ 2007 2008 ~ 2010 1 2/3 2 1 0 2 3 52 0 31 83 12 6 3 21 593 404 304 1,301 4 3 1 8 159 191 116 466 6 11 (`1: (1: 16 33 44 106

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

김범수

김범수 Analysis of Outcomes after Resection of Sarcomatous Hepatocellular Carcinoma Purpose: Sarcomatous hepatocellular carcinoma (HCC) is rare. Therefore, the clinicopathologic characteristics and prognosis

More information

- i - - ii - - iii - - iv - - v - - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - α α - 20 - α α α α α α - 21 - - 22 - - 23 -

More information

- iii - - i - - ii - - iii - 국문요약 종합병원남자간호사가지각하는조직공정성 사회정체성과 조직시민행동과의관계 - iv - - v - - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - α α α α - 15 - α α α α α α

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

012임수진

012임수진 Received : 2012. 11. 27 Reviewed : 2012. 12. 10 Accepted : 2012. 12. 12 A Clinical Study on Effect of Electro-acupuncture Treatment for Low Back Pain and Radicular Pain in Patients Diagnosed with Lumbar

More information

저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비

저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비 저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 동일조건변경허락. 귀하가이저작물을개작, 변형또는가공했을경우에는,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

Pierce-Plus-Alpha.pdf

Pierce-Plus-Alpha.pdf Save 40% on antibodies Primary antibody 전제품 40% 할인가로만나보세요 Count on Invitrogen 42,000 antibodies highly validated primary and secondary antibodies in our portfolio and growing 4,500 primary conjugated antibodies

More information

` Companies need to play various roles as the network of supply chain gradually expands. Companies are required to form a supply chain with outsourcing or partnerships since a company can not

More information

135 Jeong Ji-yeon 심향사 극락전 협저 아미타불의 제작기법에 관한 연구 머리말 협저불상( 夾 紵 佛 像 )이라는 것은 불상을 제작하는 기법의 하나로써 삼베( 麻 ), 모시( 苧 ), 갈포( 葛 ) 등의 인피섬유( 靭 皮 纖 維 )와 칠( 漆 )을 주된 재료

135 Jeong Ji-yeon 심향사 극락전 협저 아미타불의 제작기법에 관한 연구 머리말 협저불상( 夾 紵 佛 像 )이라는 것은 불상을 제작하는 기법의 하나로써 삼베( 麻 ), 모시( 苧 ), 갈포( 葛 ) 등의 인피섬유( 靭 皮 纖 維 )와 칠( 漆 )을 주된 재료 MUNHWAJAE Korean Journal of Cultural Heritage Studies Vol. 47. No. 1, March 2014, pp.134~151. Copyright 2014, National Research Institute of Cultural Heritage 심향사 극락전 협저 아미타불의 제작기법에 관한 연구 정지연 a 明 珍 素 也

More information

서강대학교 기초과학연구소대학중점연구소 심포지엄기초과학연구소

서강대학교 기초과학연구소대학중점연구소 심포지엄기초과학연구소 2012 년도기초과학연구소 대학중점연구소심포지엄 마이크로파센서를이용한 혈당측정연구 일시 : 2012 년 3 월 20 일 ( 화 ) 14:00~17:30 장소 : 서강대학교과학관 1010 호 주최 : 서강대학교기초과학연구소 Contents Program of Symposium 2 Non-invasive in vitro sensing of D-glucose in

More information

저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비

저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비 저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 동일조건변경허락. 귀하가이저작물을개작, 변형또는가공했을경우에는,

More information

00약제부봄호c03逞풚

00약제부봄호c03逞풚 경희대학교 동서신의학병원 약품 정보지 2 0 0 7. S P R I N G. V O L. 0 1 신약 소개 02 Journal Review 03 Special Subject 04 복약 지도 06 의약품 안전성 정보 07 약제부 알림 07 약제부 업무 소개 08 E A S T - W E S T N E O M E D I C A L C E N T E R 본 약품

More information

mau A B C Qsepharose051229manual001:1_UV@01,SHFT Qsepharose051229manual001:1_Conc Qsepharose051229manual001:1_Fractions Qsepharose051229manual001:1_Inject Manual run 3:1_UV@01,SHFT Manual run 3:1_Fractions

More information

<BFA9BAD02DB0A1BBF3B1A4B0ED28C0CCBCF6B9FC2920B3BBC1F62E706466>

<BFA9BAD02DB0A1BBF3B1A4B0ED28C0CCBCF6B9FC2920B3BBC1F62E706466> 001 002 003 004 005 006 008 009 010 011 2010 013 I II III 014 IV V 2010 015 016 017 018 I. 019 020 021 022 023 024 025 026 027 028 029 030 031 032 033 034 035 036 037 038 039 040 III. 041 042 III. 043

More information

( )Jkstro011.hwp

( )Jkstro011.hwp 비인강암의방사선치료결과및생존율에관한예후인자분석 2005 2 1 2005 3 28. :, Tel: 053)250-7665, Fax: 053)250-7984 E-mail: jhkim@dsmc.or.kr 정영연외 2 인 : 비인강암의예후인자분석 정영연외 2 인 : 비인강암의예후인자분석 Carcinoma of the nasopharynx treated by radiotherapy

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

step 1-1

step 1-1 Written by Dr. In Ku Kim-Marshall STEP BY STEP Korean 1 through 15 Action Verbs Table of Contents Unit 1 The Korean Alphabet, hangeul Unit 2 Korean Sentences with 15 Action Verbs Introduction Review Exercises

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

Page 2 of 5 아니다 means to not be, and is therefore the opposite of 이다. While English simply turns words like to be or to exist negative by adding not,

Page 2 of 5 아니다 means to not be, and is therefore the opposite of 이다. While English simply turns words like to be or to exist negative by adding not, Page 1 of 5 Learn Korean Ep. 4: To be and To exist Of course to be and to exist are different verbs, but they re often confused by beginning students when learning Korean. In English we sometimes use the

More information

서론

서론 - i - - ii - - iii - - iv - - v - - vi - - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - -

More information

04-다시_고속철도61~80p

04-다시_고속철도61~80p Approach for Value Improvement to Increase High-speed Railway Speed An effective way to develop a highly competitive system is to create a new market place that can create new values. Creating tools and

More information

DBPIA-NURIMEDIA

DBPIA-NURIMEDIA 27(2), 2007, 96-121 S ij k i POP j a i SEXR j i AGER j i BEDDAT j ij i j S ij S ij POP j SEXR j AGER j BEDDAT j k i a i i i L ij = S ij - S ij ---------- S ij S ij = k i POP j a i SEXR j i AGER j i BEDDAT

More information

항체 포털 서비스 Preparation Peptide 총 4주 소요 / 473,000 ~ 511,000 Free of charge 2~3 days 243,000 ~ 281,000 의뢰서 작성 Peptide epitope prediction 유전자 정보

항체 포털 서비스 Preparation Peptide 총 4주 소요 / 473,000 ~ 511,000 Free of charge 2~3 days 243,000 ~ 281,000 의뢰서 작성 Peptide epitope prediction 유전자 정보 Preparation Service AbFrontier Custom service 장점 실험 담당자와의 원활한 1:1 커뮤니케이션 (신속한 feedback을 통한 맞춤형 제작 서비스) 고객연구센터 - 개별 서비스의 진행 상황 및 결과 즉시 확인 http://center.abfrontier.com (e-mail & SMS 전송) 회원제 -연구자의 프로젝트 보안

More information

WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성 ( 황수경 ) ꌙ 127 노동정책연구 제 4 권제 2 호 pp.127~148 c 한국노동연구원 WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성황수경 *, (disabi

WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성 ( 황수경 ) ꌙ 127 노동정책연구 제 4 권제 2 호 pp.127~148 c 한국노동연구원 WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성황수경 *, (disabi WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성 ( 황수경 ) ꌙ 127 노동정책연구 2004. 제 4 권제 2 호 pp.127~148 c 한국노동연구원 WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성황수경 *, (disability)..,,. (WHO) 2001 ICF. ICF,.,.,,. (disability)

More information

<32382DC3BBB0A2C0E5BED6C0DA2E687770>

<32382DC3BBB0A2C0E5BED6C0DA2E687770> 논문접수일 : 2014.12.20 심사일 : 2015.01.06 게재확정일 : 2015.01.27 청각 장애자들을 위한 보급형 휴대폰 액세서리 디자인 프로토타입 개발 Development Prototype of Low-end Mobile Phone Accessory Design for Hearing-impaired Person 주저자 : 윤수인 서경대학교 예술대학

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

석사논문.PDF

석사논문.PDF ABO Rh A study on the importance of ABO and Rh blood groups information in Public Health 2000 2 1 ABO Rh A study on the importance of ABO and Rh blood groups information in Public Health 2000 2 2 ABO Rh

More information

김도희_HT protein expression 표준 보고서_v1.5

김도희_HT protein expression 표준 보고서_v1.5 Production of Recombinant Proteins For Further Information, Please Contact Neurogenex Co., Ltd. Biotechnology Incubating Center "Golden Helix" Seoul Natl' Univ. Seoul 151-744, Korea TEL 82-2-875-8998 FAX

More information

( )Kju269.hwp

( )Kju269.hwp 만성세균성전립선염모델흰쥐에서 의항염효과 Anti-inflammatory Effect of Lycopene on Chronic Bacterial Prostatitis Rat Model Cho Hwan Yang, Dong Wan Sohn, Yong-Hyun Cho From the Department of Urology, The Catholic University

More information

http://www.kbc.go.kr/pds/2.html Abstract Exploring the Relationship Between the Traditional Media Use and the Internet Use Mee-Eun Kang This study examines the relationship between

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

DBPIA-NURIMEDIA

DBPIA-NURIMEDIA The e-business Studies Volume 17, Number 4, August, 30, 2016:319~332 Received: 2016/07/28, Accepted: 2016/08/28 Revised: 2016/08/27, Published: 2016/08/30 [ABSTRACT] This paper examined what determina

More information

歯kjmh2004v13n1.PDF

歯kjmh2004v13n1.PDF 13 1 ( 24 ) 2004 6 Korean J Med Hist 13 1 19 Jun 2004 ISSN 1225 505X 1) * * 1 ( ) 2) 3) 4) * 1) ( ) 3 2) 7 1 3) 2 1 13 1 ( 24 ) 2004 6 5) ( ) ( ) 2 1 ( ) 2 3 2 4) ( ) 6 7 5) - 2003 23 144-166 2 2 1) 6)

More information

Kaes010.hwp

Kaes010.hwp 갑상선자극호르몬이갑상선암세포의 VEGF, 신생혈관형성, 성장, 침윤및전이에미치는영향 Effects of TSH on the Production of VEGF, Angiogenesis, Growth, Invasion and Metastasis in Thyroid Cancer Cells Euy Young Soh, M.D., Hee Boong Park, M.D.,

More information

서론 34 2

서론 34 2 34 2 Journal of the Korean Society of Health Information and Health Statistics Volume 34, Number 2, 2009, pp. 165 176 165 진은희 A Study on Health related Action Rates of Dietary Guidelines and Pattern of

More information

<C7D1B1B9B1A4B0EDC8ABBAB8C7D0BAB85F31302D31C8A35F32C2F75F303132392E687770>

<C7D1B1B9B1A4B0EDC8ABBAB8C7D0BAB85F31302D31C8A35F32C2F75F303132392E687770> 버스 외부 광고의 효과에 관한 탐색적 연구 : 매체 접촉률과 인지적 반응을 중심으로 1) 고한준 국민대학교 언론정보학부 조교수 노봉조 벅스컴애드 대표 이사 최근 몇 년 사이 옥외 광고나 인터넷 광고 등 BTL(Below the Line) 매체가 광고 시장에서 차지하 는 비중이 점점 높아지고 있다. 버스 외부 광고는 2004년 7월 서울시 교통체계개편 이후 이용자

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

- 2 -

- 2 - - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -

More information

저작자표시 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 변경금지. 귀

저작자표시 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 변경금지. 귀 저작자표시 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우, 이저작물에적용된이용허락조건을명확하게나타내어야합니다.

More information

<BFACBCBCC0C7BBE7C7D02831302031203139292E687770>

<BFACBCBCC0C7BBE7C7D02831302031203139292E687770> 延 世 醫 史 學 제12권 제2호: 29-40, 2009년 12월 Yonsei J Med Hist 12(2): 29-40, 2009 특집논문 3 한국사회의 낙태에 대한 인식변화 이 현 숙 이화여대 한국문화연구원 1. 들어가며 1998년 내가 나이 마흔에 예기치 않은 임신을 하게 되었을 때, 내 주변 사람들은 모두 들 너무나도 쉽게 나에게 임신중절을 권하였다.

More information

204 205

204 205 -Road Traffic Crime and Emergency Evacuation - 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 Abstract Road Traffic Crime

More information

아니라 일본 지리지, 수로지 5, 지도 6 등을 함께 검토해야 하지만 여기서는 근대기 일본이 편찬한 조선 지리지와 부속지도만으로 연구대상을 한정하 기로 한다. Ⅱ. 1876~1905년 울릉도 독도 서술의 추이 1. 울릉도 독도 호칭의 혼란과 지도상의 불일치 일본이 조선

아니라 일본 지리지, 수로지 5, 지도 6 등을 함께 검토해야 하지만 여기서는 근대기 일본이 편찬한 조선 지리지와 부속지도만으로 연구대상을 한정하 기로 한다. Ⅱ. 1876~1905년 울릉도 독도 서술의 추이 1. 울릉도 독도 호칭의 혼란과 지도상의 불일치 일본이 조선 근대기 조선 지리지에 보이는 일본의 울릉도 독도 인식 호칭의 혼란을 중심으로 Ⅰ. 머리말 이 글은 근대기 일본인 편찬 조선 지리지에 나타난 울릉도 독도 관련 인식을 호칭의 변화에 초점을 맞춰 고찰한 것이다. 일본은 메이지유신 이후 부국강병을 기도하는 과정에서 수집된 정보에 의존하여 지리지를 펴냈고, 이를 제국주의 확장에 원용하였다. 특히 일본이 제국주의 확장을

More information

황지웅

황지웅 Comparison of Laparoscopy and Exploration in the Distal Pancreatectomy BACKGROUND: To determine the benefits of laparoscopic surgery compared with exploration, the clinical outcomes of open and laparoscopic

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

°í¼®ÁÖ Ãâ·Â

°í¼®ÁÖ Ãâ·Â Performance Optimization of SCTP in Wireless Internet Environments The existing works on Stream Control Transmission Protocol (SCTP) was focused on the fixed network environment. However, the number of

More information

DBPIA-NURIMEDIA

DBPIA-NURIMEDIA The e-business Studies Volume 17, Number 6, December, 30, 2016:3~20 Received: 2016/12/04, Accepted: 2016/12/27 Revised: 2016/12/27, Published: 2016/12/30 [ABSTRACT] This study aims to comprehensively analyze

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

12È«±â¼±¿Ü339~370

12È«±â¼±¿Ü339~370 http://www.kbc.go.kr/ k Si 2 i= 1 Abstract A Study on Establishment of Fair Trade Order in Terrestrial Broadcasting Ki - Sun Hong (Professor, Dept. of Journalism & Mass Communication,

More information

<B3EDB9AEC1FD5F3235C1FD2E687770>

<B3EDB9AEC1FD5F3235C1FD2E687770> 경상북도 자연태음악의 소박집합, 장단유형, 전단후장 경상북도 자연태음악의 소박집합, 장단유형, 전단후장 - 전통 동요 및 부녀요를 중심으로 - 이 보 형 1) * 한국의 자연태 음악 특성 가운데 보편적인 특성은 대충 밝혀졌지만 소박집합에 의한 장단주기 박자유형, 장단유형, 같은 층위 전후 구성성분의 시가( 時 價 )형태 등 은 밝혀지지 않았으므로

More information

DBPIA-NURIMEDIA

DBPIA-NURIMEDIA 김진주 김수연. 초등학생대상장애이해교육에활용된동화에나타난장애인관분석. 특수교육, 2013, 제12권, 제2호, 135-160... 20.,,. 4.,,.,..... 주제어 : 장애이해교육, 동화, 장애인관 1. ( 1 ) Incheon Munhak Elementary School ( )(, E-mail: sooyoun@ginue.ac.kr) Dept. of

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

<BCF6BDC3323030392D31385FB0EDBCD3B5B5B7CEC8DEB0D4C5B8BFEEB5B5C0D4B1B8BBF3BFACB1B85FB1C7BFB5C0CE2E687770>

<BCF6BDC3323030392D31385FB0EDBCD3B5B5B7CEC8DEB0D4C5B8BFEEB5B5C0D4B1B8BBF3BFACB1B85FB1C7BFB5C0CE2E687770> ... 수시연구 2009-18.. 고속도로 휴게타운 도입구상 연구 A Study on the Concept of Service Town at the Expressway Service Area... 권영인 임재경 이창운... 서 문 우리나라는 경제성장과 함께 도시화가 지속적으로 진행되어 지방 지역의 인구감소와 경기의 침체가 계속되고 있습니다. 정부의 다각 적인

More information